Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Hodgkin Disease
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Hodgkin Disease
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Hodgkin Disease
Description
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. MeSH
Hierarchy View
Approved Indicated Drugs (12)
Phase 4 Indicated Drugs (4)
Phase 2 Indicated Drugs (125)
allogeneic natural killer cells
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous mesenchymal stem cells
autologous mononuclear stem cell
car-t targeted cd19/cd20/cd22/cd30
cd45-depleted allogenic peripheral blood stem cell
haplo-identical hematopoietic stem cells
human fecal microbiota (Reybota)
lmp2a-loaded conventional dc vaccine
lmp-specific cytotoxic t-lymphocytes
multi-peptide cmv-modified vaccinia ankara vaccine
Phase 1 Indicated Drugs (136)
autologous car.cd30 ebv specific-ctls
autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre
autologous dendritic cells loaded with autologous tumor lysate
autologous ebv specific cytotoxic t lymphocytes
barf1-specific cytotoxic t-lymphocytes
bcl-2 antisense oligonucleotide
c46/ccr5/p140k lentiviral vector-transduced autologous hspcs
cd34-tk75 transduced donor lymphocytes
cd56-enriched donor lymphocyte
ebna1-specific cytotoxic t-lymphocytes
genetically engineered lymphocyte therapy
lvsh5/c46 (cal-1) transduced cd34+ hematopoietic stem cells
ny-eso-1, magea4, prame, survivin and ssx - specific t cells
Other Experimental Indicated Drugs (13)
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (90)
American Scitech International
ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy
Australasian Leukaemia and Lymphoma Group
Badalona Hospital Germans Trias i Pujol
Cancer and Leukemia Group B (CALGB)
Case Western Reserve University
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Eastern Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
Fondazione Italiana Diabete Onlus
French Innovative Leukemia Organisation
Gruppo Italiano Studio Linfomi
Herbert Irving Comprehensive Cancer Center
Icahn School of Medicine at Mount Sinai
Innovent Biologics (Suzhou) Co. Ltd.
Maria Sklodowska Curie Children's Hospital
MedCenter Primary and Internal Medicine
Moorgreen Hospital, Southampton
People's Liberation Army of China
Pirogov Russian National Research Medical University
Polish Lymphoma Research Group
St. Joseph's Children's Hospital of Tampa
The Lymphoma Study Association
Université catholique de Louvain
Organization Involved with Phase 2 Indications (173)
Academic and Community Cancer Research United
Azienda Ospedaliera S. Croce e Carle Cuneo
Big Ten Cancer Research Consortium
British Columbia Cancer Agency
Center for International Blood and Marrow Transplant Research
Centro di Riferimento Oncologico - Aviano
Children's National Medical Center
City of Hope National Medical Center
Deutsche AIDS Gesellschaft e.V.
European Group for Blood and Marrow Transplantation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
German Hodgkin's Lymphoma Study Group
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI
Guangzhou Gloria Biosciences Co., Ltd.
Hôpital Maisonneuve Rosemont, Montréal, QC, Canada
Institut Català d'Oncologia, Hospital Duran i Reynals
Istituto Clinico Humanitas - Rozzano (MI), Italy
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Josep Carreras Leukaemia Research Institute
Katholieke Universiteit Leuven
Memorial Sloan-Kettering Cancer Center
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Oregon Health and Science University
Ospedale Santa Croce-Carle Cuneo
Pavlov First Saint Petersburg State Medical University
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
State University of New York, Buffalo
TaiGen Biotechnology Co., Ltd.
Taipei Veteran General hospital
The Leukemia and Lymphoma Society
Organization Involved with Phase 1 Indications (31)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
American Society of Clinical Oncology
Cancer Immunotherapy Trials Network
Organization Involved with Other Experimental Indications (12)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
